Trelegy Ellipta Dosage for COPD
For adult patients with COPD, administer Trelegy Ellipta 100/62.5/25 mcg (fluticasone furoate 100 mcg/umeclidinium 62.5 mcg/vilanterol 25 mcg) as one inhalation once daily. 1
Specific Dosing Instructions
Trelegy Ellipta 100/62.5/25 mcg is the only approved strength for COPD treatment - the higher strength formulation (200/62.5/25 mcg) is reserved exclusively for asthma patients. 1
Administration Details
- Frequency: Once daily at the same time each day
- Maximum frequency: Do not use more than once every 24 hours
- Post-inhalation care: Rinse mouth with water without swallowing to reduce oropharyngeal candidiasis risk
- Rescue medication: Use short-acting beta2-agonists (e.g., albuterol) for breakthrough shortness of breath between doses 1
No Dose Adjustments Required
The standard dose remains unchanged for:
- Geriatric patients
- Patients with renal impairment
- Patients with moderate hepatic impairment 1
Clinical Context from Guidelines
The 2017 GOLD guidelines support triple therapy (LABA/LAMA/ICS combination) as preferred initial treatment for Group D COPD patients (high symptoms, high exacerbation risk), with escalation to triple therapy for patients experiencing exacerbations on dual bronchodilator therapy. 2 This positioning aligns with Trelegy Ellipta's indication as maintenance treatment for COPD patients who require comprehensive bronchodilation and anti-inflammatory therapy.
Evidence of Effectiveness
The IMPACT trial demonstrated that this fixed-dose triple therapy regimen reduced moderate/severe exacerbations by 15% compared to ICS/LABA and by 25% compared to LAMA/LABA, with a 34% reduction in severe exacerbations requiring hospitalization versus LAMA/LABA. 3 Real-world evidence confirms sustained benefits in exacerbation reduction and healthcare resource utilization after switching from ICS/LABA dual therapy. 4
Important Safety Consideration
Be aware that triple therapy including inhaled corticosteroids increases pneumonia risk (hazard ratio 1.53 versus LAMA/LABA alone), particularly relevant for Group D patients already at higher baseline pneumonia risk. 3 This risk must be balanced against the exacerbation reduction benefits when selecting patients for triple therapy.